Literature DB >> 11584380

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

A J Freeman1, G J Dore, M G Law, M Thorpe, J Von Overbeck, A R Lloyd, G Marinos, J M Kaldor.   

Abstract

To gain a clearer understanding of the rate of progression to cirrhosis and its determinants in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic studies that incorporated assessment for cirrhosis has been undertaken. Inclusion criteria were more than 20 cases of chronic HCV infection, and information on either age of subjects or duration of infection. Of 145 studies examined, 57 fulfilled the inclusion criteria. Least-squares linear regression was employed to estimate rates of progression to cirrhosis, and to examine for factors associated with more rapid disease progression in 4 broad study categories: 1) liver clinic series (number of studies = 33); 2) posttransfusion cohorts (n = 5); 3) blood donor series (n = 10); and 4) community-based cohorts (n = 9). Estimates of progression to cirrhosis after 20 years of chronic HCV infection were 22% (95% CI, 18%-26%) for liver clinic series, 24% (11%-37%) for posttransfusion cohorts, 4% (1%-7%) for blood donor series, and 7% (4%-10%) for community-based cohorts. Factors that were associated with more rapid disease progression included older age at HCV infection, male gender, and heavy alcohol intake. Even after accounting for these factors, progression estimates were much higher for cross-sectional liver clinic series. Selection biases probably explain the higher estimates of disease progression in this group of studies. Community-based cohort studies are likely to provide a more representative basis for estimating disease progression at a population level. These suggest that for persons who acquire HCV infection in young adulthood, less than 10% are estimated to develop cirrhosis within 20 years.

Entities:  

Mesh:

Year:  2001        PMID: 11584380     DOI: 10.1053/jhep.2001.27831

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  134 in total

Review 1.  How do persistent infections with hepatitis C virus cause liver cancer?

Authors:  Jonathan K Mitchell; Stanley M Lemon; David R McGivern
Journal:  Curr Opin Virol       Date:  2015-09-29       Impact factor: 7.090

Review 2.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

3.  Hepatitis C virus replication and potential targets for direct-acting agents.

Authors:  Jacqueline G O'Leary; Gary L Davis
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

4.  Hepatitis C and general practice: the crucial role of primary care in stemming the epidemic.

Authors:  John Budd; Roy Robertson
Journal:  Br J Gen Pract       Date:  2005-04       Impact factor: 5.386

Review 5.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

6.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

7.  Impact of all oral anti-hepatitis C virus therapy: A meta-analysis.

Authors:  Siddharth Bansal; Ashwani K Singal; Brendan M McGuire; Bhupinder S Anand
Journal:  World J Hepatol       Date:  2015-04-18

8.  "Seek, test, treat and retain" for hepatitis C in the United States criminal justice system.

Authors:  Sarah Larney; Curt G Beckwith; Nickolas D Zaller; Brian T Montague; Josiah Rich
Journal:  Int J Prison Health       Date:  2014

9.  Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells.

Authors:  Hua Liang; Rodney S Russell; Nicole L Yonkers; David McDonald; Benigno Rodriguez; Clifford V Harding; Donald D Anthony
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Pegylated interferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Emilio Palumbo
Journal:  Ther Adv Chronic Dis       Date:  2011-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.